Literature DB >> 18055977

High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.

E van der Spek1, A C Bloem, H A Sinnige, H M Lokhorst.   

Abstract

In a prospective phase II study, we evaluated the combination of high dose simvastatin and VAD chemotherapy in patients with refractory or relapsed multiple myeloma. Although treatment was feasible with mild side effects, only 1 of 12 patients achieved a partial response. According to our predefined criteria this was insufficient to continue the study.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18055977     DOI： 10.3324/haematol.12071

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  4 in total

1.  Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.

Authors:  Anna Martirosyan; James W Clendening; Carolyn A Goard; Linda Z Penn
Journal:  BMC Cancer       Date:  2010-03-18       Impact factor: 4.430

Review 2.  The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.

Authors:  Borja Guerra; Carlota Recio; Haidée Aranda-Tavío; Miguel Guerra-Rodríguez; José M García-Castellano; Leandro Fernández-Pérez
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

3.  Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients.

Authors:  J M Baas; L L Krens; A J ten Tije; F Erdkamp; T van Wezel; H Morreau; H Gelderblom; H J Guchelaar
Journal:  Invest New Drugs       Date:  2015-09-19       Impact factor: 3.850

Review 4.  Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons.

Authors:  Mehdi Mohammadi; Mohammad Vaezi; Bahador Mirrahimi; Molouk Hadjibabaie
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-01-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.